Program
SPY002-072
A development code. Also written as “SPY072”.
Its studies are mostly in Hidradenitis Suppurativa · Arthritis, Rheumatoid, led by Spyre Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Spyre Therapeutics | 32 open or running | phase 2since Aug 21, 2025 | Sep 30, 2024 | Oct 2027phase 2 · NCT07766005 |
Also a collaborator on its studies: altasciences-company-inc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 30, 2024First study: phase 1 study in HealthyFirst studyNCT06622070 · 40 enrolled · United States, Canada
- Aug 21, 2025Phase 2 study in Arthritis, RheumatoidNCT07148414 · 285 enrolled · United States, Bulgaria, Czechia and more
- Aug 10, 2026Phase 2 study in Hidradenitis SuppurativaNCT07766005 · 150 planned · United States, Canada
Ahead
- Oct 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07766005
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07766005Hidradenitis Suppurativa · United States, Canada | 2 | Recruiting | Oct 2027 | 150 |
| NCT07148414Arthritis, Rheumatoid · United States, Bulgaria, Czechia and more | 2 | Active, not recruiting | Oct 31, 2026 | 285 |
| NCT06622070Healthy · United States, Canada | 1 | Completed | Jul 28, 2026 | 40 |
How it is read
Names in the registry
- “SPY002-072”, 2 entries
- “SPY072”, 1 entry
Codes read as this program: SPY072, SPY002072.
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.